/
We are a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with challenging RAS/MAPK pathway-driven cancers. We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States ( U.S. ), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous…
The business is unprofitable at the operating level (-550.33% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 209.1% YoY with margins expanding 599.2pp.
ROIC dropped from -128.65% to -152.46%, capital efficiency is deteriorating. Negative free cash flow of -$138M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$31M
▲ +209.1% YoY
Net Income (TTM)
-$194M
▼ -60.3% YoY
Op. Margin
-550.33%
▲ +599.2pp YoY
ROIC
-111.72%
▼ -23.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$151M
▼ -31.2% YoY
Op. Cash Flow (TTM)
-$151M
▼ -31.2% YoY
Net Debt
-$105M
Net Cash Position
Cash & Equiv.
$182M
5Y CAGR: +12.1%
Continue Research